Vycor Medical, Inc. filed its quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2026, with the SEC on November 13, 2026, disclosing continued stockholders' deficiency and reduced revenue compared to the prior-year period.

Key Highlights

  • Quarterly revenue of $414,895 for the three months ended September 30, 2026, down from $513,792 in the same period of 2025, according to the filing.
  • Net income from continuing operations of $1,521 for Q3 2026, compared to $4,990 in Q3 2025, the company reported.
  • Accumulated deficit reached $33,974,668 as of September 30, 2026, up from $33,648,856 at December 31, 2025.
  • Total stockholders' deficiency of $(4,412,671) as of September 30, 2026, compared to $(4,086,879) at December 31, 2025.
  • Dividends payable to related parties totaled $3,243,700 as of September 30, 2026, up from $2,919,330 at year-end 2025.
  • 33,372,796 shares of common stock outstanding as of November 13, 2026, with a par value of $0.0001 per share.

Vycor Medical Reports Narrowing Income and Growing Deficit for September 2026 Quarter

Vycor Medical, Inc. (OTCQB:VYCO), a Delaware-incorporated smaller reporting company headquartered in Boca Raton, Florida, disclosed financial results for the quarter ended September 30, 2026 in a Form 10-Q filed November 13, 2026. According to the filing, revenue for the three months ended September 30, 2026 was $414,895, compared to $513,792 for the same quarter in 2025. Nine-month revenue through September 30, 2026 was $1,291,699, versus $1,446,523 for the nine months ended September 30, 2025.

The company reported gross profit of $353,017 for Q3 2026 on cost of goods sold of $61,878, compared to gross profit of $451,932 on cost of goods sold of $61,860 in Q3 2025. Operating income for the three-month period was $27,424, versus $32,085 in the year-ago quarter. After interest expense and other items, net income from continuing operations was $1,521 for Q3 2026. Including a loss from discontinued operations of $783, net income for the quarter was $738. After preferred stock dividends of $162,185, net loss available to common stockholders was $(161,447), the filing stated.

The balance sheet as of September 30, 2026 showed total assets of $964,879 and total liabilities of $5,377,550, resulting in total stockholders' deficiency of $(4,412,671). Cash increased to $199,409 from $86,982 at December 31, 2025. Notes payable stood at $340,770 and notes payable to related parties at $493,373. The company also reported accrued interest of $604,932 and accrued interest to related parties of $207,736. The SBA EIDL loan payable was $133,038 as of September 30, 2026. Preferred stock dividends accrued during the nine months ended September 30, 2026 totaled $324,370, according to the filing.

What Was Disclosed

Vycor Medical filed its Form 10-Q for the quarter ended September 30, 2026, reporting quarterly revenue of $414,895, net income of $738, an accumulated deficit of $33,974,668, and total stockholders' deficiency of $(4,412,671) as of that date.